Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Debt (2021 - 2025)

Arcutis Biotherapeutics (ARQT) has 5 years of Total Debt data on record, last reported at $109.0 million in Q4 2025.

  • For Q4 2025, Total Debt rose 1.64% year-over-year to $109.0 million; the TTM value through Dec 2025 reached $109.0 million, up 1.64%, while the annual FY2025 figure was $109.0 million, 1.64% up from the prior year.
  • Total Debt reached $109.0 million in Q4 2025 per ARQT's latest filing, roughly flat from $108.5 million in the prior quarter.
  • Across five years, Total Debt topped out at $204.6 million in Q3 2024 and bottomed at $72.4 million in Q4 2021.
  • Average Total Debt over 5 years is $150.9 million, with a median of $196.8 million recorded in 2022.
  • Peak YoY movement for Total Debt: skyrocketed 173.35% in 2022, then crashed 46.98% in 2025.
  • A 5-year view of Total Debt shows it stood at $72.4 million in 2021, then surged by 173.35% to $197.8 million in 2022, then rose by 2.04% to $201.8 million in 2023, then tumbled by 46.88% to $107.2 million in 2024, then rose by 1.64% to $109.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $109.0 million in Q4 2025, $108.5 million in Q3 2025, and $108.0 million in Q2 2025.